|
|
|
| Effect of Different Administration Routes of Gastrodin Combined with Piracetam on Prognosis in Patients with Acute Cerebral Infarction |
| WANG Chen |
| Department of General Internal Medicine, Luodian Town Health Center of Runan County, Runan Henan 463342 |
|
|
|
|
Abstract 【Objective】 To investigate the effects of different administration routes of gastrodin combined with piracetam on the prognosis of patients with acute cerebral infarction (ACI). 【Methods】 A total of 94 patients with ACI admitted to Luodian Town Health Center of Runan County from August 2022 to August 2024 were randomly divided into an observation group and a control group, with 47 patients in each group. The observation group received intravenous infusion of gastrodin combined with piracetam, while the control group received intramuscular injection of gastrodin combined with piracetam. Clinical efficacy, incidence of adverse reactions, hemorheological parameters, inflammatory factor levels before and after treatment, and follow-up outcomes at 3 months, including activities of daily living [Activities of Daily Living Scale (ADL) score], neurological function [National Institutes of Health Stroke Scale (NIHSS) score], were compared between the two groups. 【Results】 The overall effective rate in the observation group was 93.62%, which was significantly higher than 78.72% in the control group (P<0.05). After treatment, the levels of low-shear whole blood viscosity, high-shear whole blood viscosity, and plasma viscosity in the observation group were significantly lower than those in the control group (P<0.05). The levels of interleukin-2 (IL-2), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in the observation group were significantly lower than those in the control group (P<0.05). The total incidence of adverse reactions in the observation group was lower than that in the control group, but the difference was not statistically significant (P>0.05). After 3 months of follow-up, the NIHSS score in the observation group was lower, while the ADL were higher than those in the control group (P<0.05). 【Conclusion】 Gastrodin combined with piracetam is effective and relatively safe for the treatment of ACI. However, intravenous administration provides better therapeutic efficacy and prognosis than intramuscular injection.
|
|
Received: 06 July 2025
|
|
|
|
|
|
[1] 吴婉玉,左毅,廖峻. 疏血通注射液联合吡拉西坦对高血压并急性脑梗死患者的临床疗效[J].中成药,2021, 43(5):1195-1199.
[2] 雷俊娜,程南方,李旷怡,等. 高渗氯化钠注射液联合吡拉西坦治疗急性脑梗死并脑出血临床评价[J].中国药业,2021, 30(2):86-88.
[3] 刘潇聪,张玉苗,潘亚磊. 天麻素药理作用及临床应用研究进展[J].中南药学,2024,22(6):1615-1620.
[4] 吴舒梅,李彬,李雪婷. 吡拉西坦注射液联合阿替普酶静脉溶栓治疗对急性脑梗死患者神经功能及血清miR-124水平的影响[J].检验医学与临床,2025,22(10):1297-1300.
[5] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018, 51(9):666-682.
[6] 李万华,王绍谦,刘艳,等. 苦碟子注射液联合吡拉西坦治疗急性脑梗死的临床研究[J].现代药物与临床,2023,38(5):1113-1117.
[7] 李晓杰,李新辉,袁利和,等. 吡拉西坦联合胞磷胆碱对急性脑梗死认知功能和神经功能的影响[J].现代生物医学进展,2020, 20(6):1142-1145.
[8] 郝绍江. 丹红联合天麻素治疗急性脑梗死的疗效及对患者日常生活能力等的影响[J].山西医药杂志,2019, 48(20):2515-2517.
[9] Qin W, Wang S M, YANG L, et al. Correlation between bispectral index and prognosis of patients with acute cerebral infarction[J].Curr Neurovasc Res,2021, 18(4):389-394.
[10] Sun Z, Xu Q H, Gao G R, et al. Clinical observation in edaravone treatment for acute cerebral infarction[J].Niger J Clin Pract,2019, 22(10):1324-1327.
[11] Zhang Z F, Liu W J, Chai Z M, et al. Therapeutic effect of piracetam with nimodipine on vascular dementia after cerebral infarction[J].Pak J Pharm Sci,2020, 33(5):2405-2411.
[12] 刘承国,李露,邹川. 氧化应激在急性脑损伤发病机制中的作用[J].基础医学与临床,2026,46(5):721-725.
[13] 张金才,孙照芬,史福俊. 天麻素注射液联合尼莫地平治疗急性脑梗死的临床疗效及其对患者炎症因子、血管内皮因子的影响[J].实用心脑肺血管病杂志,2024,32(4):51-55.
[14] Wen H J, Lyu M. Correlation analysis between serum procalcitonin and infarct volume in young patients with acute cerebral infarction[J].Neurol Sci,2021, 42(8):3189-3196. |
|
|
|
2026, Vol. 43 
